Dr. Pinter-Brown Discusses Treatment Decisions for CTCL | OncLive

Dr. Pinter-Brown Discusses Treatment Decisions for CTCL

May 14, 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma (CTCL). At the 17th International Congress on Hematologic Malignancies, Pinter-Brown spoke about the factors that weigh into a physician's decision concerning the treatment of CTCL.

A physician needs to understand which CTCL is being treated. The stage of the disease is also crucial, as it determines whether the disease needs local or systemic treatment. Other considerations include comorbidities, route of administration, and availability of treatment. A physician must also be aware of how quickly a treatment works and how quickly a patient needs a response.


x